A Randomised Controlled Trial of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration

NCT02060604 Phase 4 COMPLETED

The addition of an anti-inflammatory agent could be a valid option for controlling choroidal neovascularization, as simply inhibiting VEGF addresses neither the multifactorial pathogenesis of choroidal neovascularization nor the underlying cause of VEGF production.

Details

Lead sponsor	Università degli Studi di Brescia
Phase	Phase 4
Status	COMPLETED
Enrolment	60
Start date	2012-12
Completion	2014-01

Conditions

• Wet Macular Degeneration

Interventions

• Ketorolac + Ranibizumab
• Ranibizumab

Primary outcomes

• mean change in study eye visual acuity as measured by the best-corrected ETDRS letter score — 12 months

Countries

Italy